Influence of reduced muscle mass and quality on ventilator weaning and complications during intensive care unit stay in COVID-19 patients.
COVID-19
Intensive care unit
Muscle mass
Muscle quality
Ventilator weaning
Journal
Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
22
04
2021
revised:
02
08
2021
accepted:
09
08
2021
pubmed:
2
9
2021
medline:
7
12
2022
entrez:
1
9
2021
Statut:
ppublish
Résumé
Sarcopenia, a loss of muscle mass, quality and function, which is particularly evident in respiratory muscles, has been associated with many clinical adverse outcomes. In this study, we aimed at evaluating the role of reduced muscle mass and quality in predicting ventilation weaning, complications, length of intensive care unit (ICU) and of hospital stay and mortality in patients admitted to ICU for SARS-CoV-2-related pneumonia. This was an observational study based on a review of medical records of all adult patients admitted to the ICU of a tertiary hospital in Milan and intubated for SARS-CoV-2-related pneumonia during the first wave of the COVID-19 pandemic. Muscle mass and quality measurement were retrieved from routine thoracic CT scans, when sections passing through the first, second or third lumbar vertebra were available. A total of 81 patients were enrolled. Muscle mass was associated with successful extubation (OR 1.02, 95% C.I. 1.00-1.03, p = 0.017), shorter ICU stay (OR 0.97, 95% C.I. 0.95-0.99, p = 0.03) and decreased hospital mortality (HR 0.98, 95% C.I. 0.96-0.99, p = 0.02). Muscle density was associated with successful extubation (OR 1.07, 95% C.I. 1.01-1.14; p = 0.02) and had an inverse association with the number of complications in ICU (Β -0.07, 95% C.I. -0.13 - -0.002, p = 0.03), length of hospitalization (Β -1.36, 95% C.I. -2.21 - -0.51, p = 0.002) and in-hospital mortality (HR 0.88, 95% C.I. 0.78-0.99, p = 0.046). Leveraging routine CT imaging to measure muscle mass and quality might constitute a simple, inexpensive and powerful tool to predict survival and disease course in patients with COVID-19. Preserving muscle mass during hospitalisation might have an adjuvant role in facilitating remission from COVID-19.
Sections du résumé
BACKGROUND & AIMS
Sarcopenia, a loss of muscle mass, quality and function, which is particularly evident in respiratory muscles, has been associated with many clinical adverse outcomes. In this study, we aimed at evaluating the role of reduced muscle mass and quality in predicting ventilation weaning, complications, length of intensive care unit (ICU) and of hospital stay and mortality in patients admitted to ICU for SARS-CoV-2-related pneumonia.
METHODS
This was an observational study based on a review of medical records of all adult patients admitted to the ICU of a tertiary hospital in Milan and intubated for SARS-CoV-2-related pneumonia during the first wave of the COVID-19 pandemic. Muscle mass and quality measurement were retrieved from routine thoracic CT scans, when sections passing through the first, second or third lumbar vertebra were available.
RESULTS
A total of 81 patients were enrolled. Muscle mass was associated with successful extubation (OR 1.02, 95% C.I. 1.00-1.03, p = 0.017), shorter ICU stay (OR 0.97, 95% C.I. 0.95-0.99, p = 0.03) and decreased hospital mortality (HR 0.98, 95% C.I. 0.96-0.99, p = 0.02). Muscle density was associated with successful extubation (OR 1.07, 95% C.I. 1.01-1.14; p = 0.02) and had an inverse association with the number of complications in ICU (Β -0.07, 95% C.I. -0.13 - -0.002, p = 0.03), length of hospitalization (Β -1.36, 95% C.I. -2.21 - -0.51, p = 0.002) and in-hospital mortality (HR 0.88, 95% C.I. 0.78-0.99, p = 0.046).
CONCLUSIONS
Leveraging routine CT imaging to measure muscle mass and quality might constitute a simple, inexpensive and powerful tool to predict survival and disease course in patients with COVID-19. Preserving muscle mass during hospitalisation might have an adjuvant role in facilitating remission from COVID-19.
Identifiants
pubmed: 34465493
pii: S0261-5614(21)00375-7
doi: 10.1016/j.clnu.2021.08.004
pmc: PMC8364854
pii:
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2965-2972Informations de copyright
Copyright © 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest None.
Références
Clin Nutr. 2019 Feb;38(1):48-79
pubmed: 30348463
Support Care Cancer. 2016 Nov;24(11):4721-6
pubmed: 27364150
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
J Appl Physiol (1985). 2004 Dec;97(6):2333-8
pubmed: 15310748
Ageing Res Rev. 2017 Jul;36:1-10
pubmed: 28223244
Respir Physiol Neurobiol. 2016 Jun;226:137-46
pubmed: 26467183
Nephrology (Carlton). 2013 Jun;18(6):468-473
pubmed: 23590458
Clin Nutr. 2017 Dec;36(6):1649-1653
pubmed: 27789123
Lancet. 2013 Mar 2;381(9868):752-62
pubmed: 23395245
Ann Surg Oncol. 2018 Jan;25(1):308-317
pubmed: 29116490
Clin Nutr. 2021 Mar;40(3):1330-1337
pubmed: 32900518
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Br J Surg. 2016 Mar;103(4):434-42
pubmed: 26780231
J Physiol. 2015 Sep 15;593(18):4259-73
pubmed: 26173027
J Geriatr Oncol. 2021 Apr;12(3):467-469
pubmed: 32994139
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):181-90
pubmed: 22865205
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Intensive Care Med. 2004 Jul;30(7):1334-9
pubmed: 14999444
Respir Med. 2004 Jul;98(7):661-8
pubmed: 15250233
Clin Nutr. 2020 Sep;39(9):2764-2770
pubmed: 31917051
Curr Probl Cancer. 2020 Apr;44(2):100510
pubmed: 31703987
Int J Chron Obstruct Pulmon Dis. 2019 Apr 03;14:781-789
pubmed: 31040657
Intensive Care Med. 2011 Dec;37(12):1976-85
pubmed: 21976188
Crit Care Med. 2013 Jun;41(6):1543-54
pubmed: 23528802
Am J Respir Crit Care Med. 2000 May;161(5):1530-6
pubmed: 10806150
Oral Oncol. 2016 Nov;62:28-33
pubmed: 27865369
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
Aging Dis. 2020 Dec 1;11(6):1345-1351
pubmed: 33269092
J Crit Care. 2012 Apr;27(2):221.e1-8
pubmed: 21958979
Support Care Cancer. 2018 Jul;26(7):2353-2359
pubmed: 29417293
Crit Care Med. 2015 Mar;43(3):613-20
pubmed: 25479115
Acta Physiol (Oxf). 2014 Mar;210(3):489-97
pubmed: 24393306
Int J Obes (Lond). 2015 Mar;39(3):379-86
pubmed: 25174451
Br J Nutr. 2022 Mar 14;127(5):722-735
pubmed: 33910664
Sci Rep. 2018 Jul 27;8(1):11369
pubmed: 30054580
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Am J Physiol Lung Cell Mol Physiol. 2015 Jul 1;309(1):L46-52
pubmed: 25934669
Crit Care Med. 1989 Sep;17(9):858-61
pubmed: 2766756
Nat Commun. 2015 Dec 15;6:10145
pubmed: 26666572
Physiol Rep. 2020 Jan;8(1):e14305
pubmed: 31908152
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Panminerva Med. 2022 Jun;64(2):244-252
pubmed: 33073557
J Appl Physiol (1985). 2000 Jul;89(1):104-10
pubmed: 10904041
BMC Geriatr. 2008 Sep 30;8:24
pubmed: 18826625
Chest. 2018 Apr;153(4):1040-1051
pubmed: 28887062
J Crit Care. 2012 Jun;27(3):324.e1-7
pubmed: 21798702
Int J Hematol. 2021 Jul;114(1):44-52
pubmed: 33694061
Eur J Cardiothorac Surg. 2019 Mar 1;55(3):414-420
pubmed: 30289481
J Appl Physiol (1985). 1997 Jul;83(1):229-39
pubmed: 9216968